AngioDynamics (ANGO) awards RSUs and performance rights to senior VP Campbell
Rhea-AI Filing Summary
AngioDynamics Inc. reported that officer Chad Thomas Campbell, SVP/GM Vascular Access, received equity awards on July 15, 2026. He acquired 16,081 restricted stock units, each convertible into one share of common stock, vesting in four equal annual installments on July 15 of 2027, 2028, 2029 and 2030. He also received 16,081 performance rights, each representing a contingent right to one share, with 0–200% of the target (plus a possible 20% adjustment, for up to 240% of target) earned based on three-year total shareholder return relative to a peer group. Following these grants, he directly held 104,540 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 16,081 shares
Net Buy
2 txns
Insider
Campbell Chad Thomas
Role
SVP/GM, Vascular Access
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance Right F2 | 16,081 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 16,081 | $0.00 | $0.00 |
Holdings After Transaction:
Performance Right — 16,081 shares (Direct);
Common Stock — 104,540 shares (Direct)
Footnotes (2)
- F1. The acquisition of 16,081 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 16,081 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
- F2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
Key Figures
Restricted stock units granted: 16,081 units
Performance rights target: 16,081 rights
RSU vesting schedule: 25% annually 2027–2030
+3 more
6 metrics
Restricted stock units granted
16,081 units
Time-based RSUs granted to Chad Thomas Campbell on July 15, 2026
Performance rights target
16,081 rights
Target number of performance rights tied to common stock
RSU vesting schedule
25% annually 2027–2030
RSUs vest in four equal annual installments starting July 15, 2027
Performance payout range
0%–240% of target
0%–200% based on TSR plus possible 20% adjustment
Campbell common shares after grant
104,540 shares
Direct common stock holdings following July 15, 2026 acquisition
Performance period length
3 years
Total shareholder return measured over a three-year performance period
Key Terms
restricted stock units, performance right, total shareholder return, peer group of companies
4 terms
restricted stock units financial
"represents 16,081 restricted stock units, each of which represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance right financial
"Each performance right represents a contingent right to receive one share"
peer group of companies financial
"return relative to a peer group of companies over a three-year performance period"
FAQ
What equity awards did AngioDynamics (ANGO) grant to Chad Thomas Campbell?
AngioDynamics granted Chad Thomas Campbell 16,081 restricted stock units and 16,081 performance rights. Each unit or right represents a contingent claim to one share of common stock, subject to time-based vesting and performance conditions over several years.
How do the restricted stock units for AngioDynamics (ANGO) SVP Campbell vest?
The 16,081 restricted stock units vest in four equal annual installments. Exactly 25% of the RSUs vest on each of July 15, 2027, 2028, 2029, and 2030, provided the vesting conditions are satisfied at each date.
What performance conditions apply to Campbell’s AngioDynamics (ANGO) performance rights?
Each performance right is tied to total shareholder return versus a peer group over a three-year performance period. Between 0% and 200% of target can be earned, with a possible 20% adjustment, for up to 240% of target in total.
What happens to AngioDynamics (ANGO) performance rights that do not vest for Campbell?
Any performance rights that do not vest by the end of the three-year performance period are forfeited. The number of shares ultimately earned depends on total shareholder return performance and the potential 20% adjustment applied to calculated achievement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
